focus -WSS

focus

author：focus 2025-09-30 08:52:02 - browse：953

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Sudafed saga points to U.S. issues with evaluating older drugs

leisure time

WSS

Menendez indictment could see pharma lose a key ally

Why do women spend more than men on medical expenses?

Data show record exodus of life scientists from academia

Paxlovid should be available without a positive Covid test

FDA advisers vote against ALS treatment from BrainStorm

Ionis has late

explore

focus

hotspot

How to save PrEP access — and even expand it

Elizabeth Holmes banned from government health programs

How one medical school became remarkably diverse

FDA advisers vote against ALS treatment from BrainStorm

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Covid vaccines: Private market messier than government rollout

Heart attack and stroke risk calculators need revising

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Cancer drug shortages should be causing more outrage

Inequities make cancer less preventable for women: report

focus

FDA seeks to regulate lab

WHO recommends dropping component of many flu vaccines

Why do women spend more than men on medical expenses?

Biogen shutters digital health group, ends Apple study, in cost cutting move

Medicare Advantage today, explained in one chart

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

hotspot

knowledge

leisure time

hotspot